相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Cancer statistics, 2022
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2022)
Evolving strategies for management of desmoid tumor
Richard F. Riedel et al.
CANCER (2022)
Phase II trial of palbociclib in advanced sarcoma overexpressing CDK4 gene excluding dedifferentiated liposarcoma (DD LPS): A study from the Spanish Group for Research on Sarcoma (GEIS).
Javier Martin Broto et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Updated analysis of the efficacy and safety of entrectinib in patients (pts) with locally advanced/metastatic NTRK fusion-positive (NTRK-fp) solid tumors.
Maciej Jerzy Krzakowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
A phase Ia/Ib, dose-escalation/expansion study of the MDM2–p53 antagonist BI 907828 in patients with solid tumors, including advanced/metastatic liposarcoma (LPS).
Mrinal M. Gounder et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
nab-Sirolimus for patients with advanced malignant PEComa with or without prior mTOR inhibitors: Biomarker results from AMPECT and an expanded access program.
Mark Andrew Dickson et al.
JOURNAL OF CLINICAL ONCOLOGY (2022)
Soft Tissue Sarcoma, Version 2.2022
Margaret von Mehren et al.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK (2022)
Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase II expansion
J-Y. Blay et al.
ANNALS OF ONCOLOGY (2022)
Initial results of phase II/III trial of AL102 for treatment of desmoid tumors (DT)
M. M. Gounder et al.
ANNALS OF ONCOLOGY (2022)
A Single-Arm Phase Ib/II Study of Lenvatinib plus Eribulin in Advanced Liposarcoma and Leiomyosarcoma
Tom Wei-Wu Chen et al.
CLINICAL CANCER RESEARCH (2022)
The emerging role of cancer nanotechnology in the panorama of sarcoma
Laura Mercatali et al.
FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY (2022)
nab-Sirolimus for Patients With Malignant Perivascular Epithelioid Cell Tumors
Andrew J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
Robert Motzer et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities
Silvia Stacchiotti et al.
CANCER (2021)
A Phase I/II Study to Assess the Safety and Efficacy of Pazopanib and Pembrolizumab Combination Therapy in Patients with Advanced Renal Cell Carcinoma
Simon Chowdhury et al.
CLINICAL GENITOURINARY CANCER (2021)
The potential role of the extracellular matrix in the activity of trabectedin in UPS and L-sarcoma: evidences from a patient-derived primary culture case series in tridimensional and zebrafish models
Alessandro De Vita et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2021)
Anlotinib: A Novel Targeted Drug for Bone and Soft Tissue Sarcoma
Shenglong Li
FRONTIERS IN ONCOLOGY (2021)
Safety and preliminary efficacy of vimseltinib in tenosynovial giant cell tumor (TGCT)
H. Gelderblom et al.
ANNALS OF ONCOLOGY (2021)
An open-label single-arm phase II study of regorafenib for the treatment of angiosarcoma
Mark Agulnik et al.
EUROPEAN JOURNAL OF CANCER (2021)
A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.
Brian Andrew Van Tine et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Vimseltinib: A Precision CSF1R Therapy for Tenosynovial Giant Cell Tumors and Diseases Promoted by Macrophages
Bryan D. Smith et al.
MOLECULAR CANCER THERAPEUTICS (2021)
Activity of the Gamma Secretase Inhibitor AL101 in Desmoid Tumors: A Case Report of 2 Adult Cases
David Chan et al.
CURRENT ONCOLOGY (2021)
Anti-tumor activity of the MDM2-TP53 inhibitor BI-907828 in dedifferentiated liposarcoma patient-derived xenograft models harboring MDM2 amplification
J. Cornillie et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2020)
Doxorubicin plus dacarbazine, doxorubicin plus ifosfamide, or doxorubicin alone as a first-line treatment for advanced leiomyosarcoma: A propensity score matching analysis from the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group
Lorenzo D'Ambrosio et al.
CANCER (2020)
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials
Robert C. Doebele et al.
LANCET ONCOLOGY (2020)
Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas The ANNOUNCE Randomized Clinical Trial
William D. Tap et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2020)
Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
M.M. Gounder et al.
EUROPEAN JOURNAL OF CANCER (2020)
Randomized Comparison of Pazopanib and Doxorubicin as First-Line Treatment in Patients With Metastatic Soft Tissue Sarcoma Age 60 Years or Older: Results of a German Intergroup Study
Viktor Gruenwald et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Tazemetostat in advanced epithelioid sarcoma with loss of INI1/SMARCB1: an international, open-label, phase 2 basket study
Mrinal Gounder et al.
LANCET ONCOLOGY (2020)
Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma A Phase 1/2 Nonrandomized Clinical Trial
Seth M. Pollack et al.
JAMA ONCOLOGY (2020)
Management of Tenosynovial Giant Cell Tumor: A Neoplastic and Inflammatory Disease
John H. Healey et al.
JOURNAL OF THE AMERICAN ACADEMY OF ORTHOPAEDIC SURGEONS GLOBAL RESEARCH AND REVIEWS (2020)
A Phase II Trial of Pazopanib in Patients with Metastatic Alveolar Soft Part Sarcoma
Miso Kim et al.
ONCOLOGIST (2019)
CDK 4/6 Inhibitors in Breast Cancer: Current Controversies and Future Directions
Laura M. Spring et al.
CURRENT ONCOLOGY REPORTS (2019)
Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): a randomised phase 3 trial
William D. Tap et al.
LANCET (2019)
Pazopanib or methotrexate-vinblastine combination chemotherapy in adult patients with progressive desmoid tumours (DESMOPAZ): a non-comparative, randomised, open-label, multicentre, phase 2 study
Maud Toulmonde et al.
LANCET ONCOLOGY (2019)
Comparative Assessment of Antitumor Effects and Autophagy Induction as a Resistance Mechanism by Cytotoxics and EZH2 Inhibition in INI1-Negative Epithelioid Sarcoma Patient-Derived Xenograft
Silvia Stacchiotti et al.
CANCERS (2019)
Imatinib Treatment for Locally Advanced or Metastatic Dermatofibrosarcoma Protuberans A Systematic Review
Cristian Navarrete-Dechent et al.
JAMA DERMATOLOGY (2019)
Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study
Carlo Gambacorti-Passerini et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
The SS18-SSX Fusion Oncoprotein Hijacks BAF Complex Targeting and Function to Drive Synovial Sarcoma
Matthew J. McBride et al.
CANCER CELL (2018)
Safety and Efficacy of Anlotinib, a Multikinase Angiogenesis Inhibitor, in Patients with Refractory Metastatic Soft-Tissue Sarcoma
Yihebali Chi et al.
CLINICAL CANCER RESEARCH (2018)
Synovial Sarcoma: Current Concepts and Future Perspectives
Silvia Stacchiotti et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study
Antoine Italiano et al.
LANCET ONCOLOGY (2018)
Efficacy of Larotrectinib in TRK Fusion-Positive Cancers in Adults and Children
A. Drilon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
Anthony B. El-Khoueiry et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Activity and safety of crizotinib in patients with advanced, metastatic alveolar soft part sarcoma (ASPS) with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 90101 CREATE.
Patrick Schoffski et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A non-canonical SWI/SNF complex is a synthetic lethal target in cancers driven by BAF complex perturbation
Brittany C. Michel et al.
NATURE CELL BIOLOGY (2018)
NTRK fusion-positive cancers and TRK inhibitor therapy
Emiliano Cocco et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Sorafenib for Advanced and Refractory Desmoid Tumors
Mrinal M. Gounder et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Targeted degradation of BRD9 reverses oncogenic gene expression in synovial sarcoma
Gerard L. Brien et al.
ELIFE (2018)
Clinical Activity of the γ-Secretase Inhibitor PF-03084014 in Adults With Desmoid Tumors (Aggressive Fibromatosis)
Shivaani Kummar et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Long-term results of treatment of advanced dermatofibrosarcoma protuberans (DFSP) with imatinib mesylate - The impact of fibrosarcomatous transformation
P. Rutkowski et al.
EJSO (2017)
Patient-reported Symptoms of Tenosynovial Giant Cell Tumors
Heather L. Gelhorn et al.
CLINICAL THERAPEUTICS (2016)
PICASSO III: A Phase III, Placebo-Controlled Study of Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma
Christopher W. Ryan et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Safety, pharmacokinetics, and antitumor properties of anlotinib, an oral multi-target tyrosine kinase inhibitor, in patients with advanced refractory solid tumors
Yongkun Sun et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2016)
Safety and efficacy of regorafenib in patients with advanced soft tissue sarcoma (REGOSARC): a randomised, double-blind, placebo-controlled, phase 2 trial
Olivier Mir et al.
LANCET ONCOLOGY (2016)
Progression-Free Survival Among Patients With Well-Differentiated or Dedifferentiated Liposarcoma Treated With CDK4 Inhibitor Palbociclib A Phase 2 Clinical Trial
Mark A. Dickson et al.
JAMA ONCOLOGY (2016)
Targeting the Notch pathway: A potential therapeutic approach for desmoid tumors
Hui Shang et al.
CANCER (2015)
A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors
Shinji Nakamichi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2015)
Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma
David S. Hong et al.
CLINICAL CANCER RESEARCH (2015)
Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial
Jin Li et al.
LANCET ONCOLOGY (2015)
Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor
W. D. Tap et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a randomised controlled phase 3 trial
Ian Judson et al.
LANCET ONCOLOGY (2014)
The landscape of kinase fusions in cancer
Nicolas Stransky et al.
NATURE COMMUNICATIONS (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
Reversible Disruption of mSWI/SNF (BAF) Complexes by the SS18-SSX Oncogenic Fusion in Synovial Sarcoma
Cigall Kadoch et al.
CELL (2013)
Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial
George D. Demetri et al.
LANCET (2013)
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial
Axel Grothey et al.
LANCET (2013)
Safety and activity of crizotinib for paediatric patients with refractory solid tumours or anaplastic large-cell lymphoma: a Children's Oncology Group phase 1 consortium study
Yael P. Mosse et al.
LANCET ONCOLOGY (2013)
Sunitinib malate in solitary fibrous tumor (SFT)
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2012)
Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis
Philippe A. Cassier et al.
CANCER (2012)
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
Winette T. A. van der Graaf et al.
LANCET (2012)
Sunitinib in advanced alveolar soft part sarcoma: evidence of a direct antitumor effect
S. Stacchiotti et al.
ANNALS OF ONCOLOGY (2011)
Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity
Scott M. Wilhelm et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Clinical Activity of mTOR Inhibition With Sirolimus in Malignant Perivascular Epithelioid Cell Tumors: Targeting the Pathogenic Activation of mTORC1 in Tumors
Andrew J. Wagner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imatinib Mesylate in Advanced Dermatofibrosarcoma Protuberans: Pooled Analysis of Two Phase II Clinical Trials
Piotr Rutkowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Can MDM2 analytical tests performed on core needle biopsy be relied upon to diagnose well-differentiated liposarcoma?
Joshua Weaver et al.
MODERN PATHOLOGY (2010)
Reduced expression of SMARCB1/INI1 protein in synovial sarcoma
Kenichi Kohashi et al.
MODERN PATHOLOGY (2010)
The diagnostic value of SYT-SSX detected by reverse transcriptase-polymerase chain reaction (RT-PCR) and fluorescence in situ hybridization (FISH) for synovial sarcoma:: A review and prospective study of 255 cases
Baocun Sun et al.
CANCER SCIENCE (2008)
PEComas: the past, the present and the future
Guido Martignoni et al.
VIRCHOWS ARCHIV (2008)
Molecular identification of COL6A3-CSFI fusion transcripts in tenosynovial giant cell tumors
Emely Moller et al.
GENES CHROMOSOMES & CANCER (2008)
Activation of the mTOR pathway in sporadic angiomyolipomas and other perivascular epithelioid cell neoplasms
Heidi Kenerson et al.
HUMAN PATHOLOGY (2007)
Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity
Rakesh Kumar et al.
MOLECULAR CANCER THERAPEUTICS (2007)
Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides
John S. Cupp et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2007)
An orally available small-molecule inhibitor of c-met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms
Helen Y. Zou et al.
CANCER RESEARCH (2007)
MDM2 inhibitors for cancer therapy
Lyubomir T. Vassilev
TRENDS IN MOLECULAR MEDICINE (2007)
A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells
RB West et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Prognostic factors for patients with localized soft-tissue sarcoma treated with conservation surgery and radiation therapy - An analysis of 1225 patients
GK Zagars et al.
CANCER (2003)
分享论文
